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D 4.3.1 Introduction
For decades, pharmaceutical and clinical research aimed at improving the morbidity of claudica-
tion has centered around vasodilators. Direct-acting vasodilators can increase blood flow in nor-
mal resting skeletal muscle. However, it is unlikely that any vasodilator can significantly increase
blood flow distal to a physical occlusion. Autoregulatory mechanisms in skeletal muscle beds
produce dilation in response to ischemia; hence, vasodilators will increase blood flow primarily
to nonischemic areas. The concept of vasodilatation has moved to vasoreactive or vasorecruiting
drugs and more recently to agents improving unbalanced or compromised microcirculation dis-
tal to an arterial obstruction. Another approach is to search for compounds that improve the
blood rheology. The use of thrombolytic drugs in CLI is also to be considered, most often to
be followed by endovascular or surgical treatment.
The ideal treatment for critical limb ischemia must be the elimination or bypass of the occlu-
sions in the larger arteries, but this is often impossible or else it fails. An alternative in these
cases is to try to modify the consequences of the low perfusion pressure on the distal microcir-
culation sufficiently by some form of pharmacotherapy to reverse the rest pain and avoid ampu-
tation.
Pharmacological management of CLI must be based on an improved understanding of its
pathophysiology. The main components, lack of autoregulation of the microvascular flow-regu-
lating system and inappropriate activation of the microvascular defense system, are both thought
to be significantly regulated by prostacyclin.! Breakdown of the microvascular flow-regulating
system is manifested in particular by abnormal vasomotion and a maldistribution of blood flow
away from the nutritive skin capillaries. Activation of the microvascular defense system results in
interacting activation of white blood cells, platelets, and the damaged endothelium. The resul-
tant capillary obstruction, increased capillary permeability, tissue edema, and the liberation of
activated products of leukocytes, such as oxygen free radicals, platelet-activating factor, and pro-
teolytic enzymes, leads to a vicious cycle with further capillary obstruction.
D 4.3.2 Prostanoids
Prostanoids have been shown to have beneficial effects on most of the microcirculatory compo-
nents by preventing the reciprocal potentiation of platelet activation, leukocyte activation, and
the damaged vascular endothelium. 1 This is probably the reason why prostanoids have, in the
last few years, been the most widely tested group of drugs in this condition. Initially, PGE1 was
mainly evaluated by intraarterial administration because of its well-known rapid pulmonary inac-
tivation.s Intravenous studies with PGE1 were subsequently undertaken when it was shown that
after a temporary inactivation ofPGEl by the lung, 13,14-dihydro-PGE1 is formed. At least in
regard to antiplate1et activity, this has been shown to display biological activity comparable with
the parent compound PGE1.3 Furthermore, intraarterial and intravenously infused PGEl in
patients with intermittent claudication caused a similar systemic inhibition of zymosan-stimulat-
ed radical production.t The clinical benefit of the intravenous administration route was later
shown in a limited number of patients with PAD stage III in a single German center by Diehm
et al.5
Since the first report of the effects of intraarterial infusion of prostaglandin E1 in four patients with
unreconstructable leg ischemia.s there have been seven short-term (3-4 days) trials using PGE1 and
PGI2 intraarterially7,8,9 or intravenouslylO,1l,12,l3 showing inconclusive evidence of their efficacyin
patients with unreconstructable limb ischemia. Table 41 summarizes 13 subsequently performed
long-term randomized open or double-blind trials comparing intraarterial or intravenous infusions
of PGE1, ciprostene, or iloprost, both more stable prostacyclin analogs, with placebo in patients
with advanced chronic limb ischemia (Fontaine stages III and N).5,14,15,16,17,18,19,20,21,22,23,24,25,26
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Table 41: Trials comparing long-term (7-28 days' treatment) infusion of prostanoid with placebo or refer-
ence drug in patients with severe arterial disease (Fontaine III and IV) 14
n Trial
Author (% diabetic) Drug Dosage Follow-up End points Results p design
Sakaguchi 65 PGE 1 (IA) 0.05 or 0.15 end of ulcer size reduced by 0.039 DB
198415 niacinate oral ng/kg/min x 24 infusion pain higher dose
(200 mg continuous infusion vs, niacinate
6 x daily) for :2-6 wk + lower dose
Bohrne et al, 34 PGE 1 (IA) 10-20 pg/60 end of ulcer size reduced NS a
198716 vsATP min x 23 days infusion rest pain reduced NS
Trubestein et al, 57 PGE 1 vs 30 20 mg over 60 3wk analg. cons. reduced <: 0.04 a
198717 mgATP (IA) min daily x 3 wk ulcer size reduced <: 0.02
amputation reduced 0.02
Diehm et al, 46 PGE 1 vs 60 pg/4 h/ 1 mo pain reduced -c 0.04 DB
19885 placebo (IV) day x 3 wk analg. cons. reduced <: 0.02
clinical stage improved 0.007
Ciprostene Study 211 PGE 1 vs 120 ng/kg/min 4mo ulcer size reduced -c 0.005 DB
Group 1991 18 placebo (IV) x 8 h/day x 7 days by 50%
lCAI Study 1,560 PGE 1 (IV) vs 60 pg/day 6 mo CLI reduced odds 0.002 a
Group, 1998 19 routine x 28 days disappearance ratio 0.73
treatment
Trtibestein et al, 70 PGE 1 (IV) 2 x 40 ug over 6 mo rest pain reduced NS a
198920 vs pentoxifylline 2 h daily x 4 wk analg. cons. reduced <: 0.005
ulcer size reduced <: 0.05
Balzer et al, 113 Iloprost vs 0.5-2 ng/kg/min end of analg, cons. reduced < 0.05 DB
198721 (34%) placebo (IV) x 6 h X 14 days i.nfusion
Diehm er al, 101 Iloprost vs up to 2 ng/kg/ end of ulcer size reduced < 0.05 DB
198922 placebo (IV) min x 6 h x 28 days infusion
Norgren et al, 103 Iloprost vs 0.5-2 ng/kg/min 6 mo ulcer size reduced NS DB
199023 (32%) placebo (IV) x 6 h x 14 days
Brock et ai, 109 Iloprost vs 0.5-2 ng/kg/min end of ulcer size reduced < 0.05 DB
199024 (100%) placebo (IV) x 6 h x 28 days infusion rest pain reduced < 0.05
UK Study Group, 151 Iloprost vs up to 2 ng/kg/min 1 mo ulcer healing reduced < 0.05 DB
199125 (31%) placebo (IV) x 6 h daily x 28 days 6 mo ulcer healing reduced < 0.01
Guilmot et al, 128 Iloprost vs up to 2 ng/kg/min 1 rno rest pain Reduced < 0.05 DB
199126 (58%) placebo (IV) x 6 hr daily x 21 days 1 rna rest pain Reduced NS
NS=not statistically significant; PG12=prostaglandin 12; PGE 1=prostaglandin E1; analg cons-analgesic consumption; Cl.Iecrirical limb
ischemia; a-open; DB-double-blind
These studies all followed a similar protocol, although the duration of treatment varied from 2
to 4 weeks. The clinical end points used were relief of rest pain, analgesic consumption, or pro-
motion of ulcer healing. All of these long-term studies administering prostanoids for more than
7 days showed a benefit in at least one of the chosen end points, with only two trials failing to
reach statistical significance. The response seemed to be greater when prostanoids were adminis-
tered for 4 weeks, compared with administration for 2 or 3 weeks, Data on major amputation at
3 or 6 months' follow-up were available in three of the iloprost studies. 23,25,26 Patients who
received iloprost were significantly less likely to have undergone a major amputation than
patients in the placebo groups (23% vs 39%, p < 0.05) during the treatment and follow-up peri-
od, Most importantly, patients who received iloprost had a significantly greater probability of
completing the follow-up period alive with both legs than patients who received placebo (35%
vs 55%, P < 0.05).27
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Although these results are impressive, it is also important to be aware of their limitations. Total
ulcer healing was not used because it was too uncommon an event after a few weeks of treat-
ment. Measurement of the decrease in greatest diameter of the ulcer is subject to observer varia-
tion. Furthermore, where photographs were used in attempt to overcome observer variation,
they were often of inconsistent quality. With respect to pain relief, it has to be kept in mind that
this outcome measure is based on a subjective assessment by the individual patient. A further
bias may have been introduced by the side effects of prostanoids, allowing the observer to have
an idea of the patient's treatment group. Further clinical trials with prostanoids are required to
show evidence of efficacy as primary medical treatment of elitical limb ischemia.
The prostanoid investigated in the largest number of patients with advanced chronic limb
ischemia in controlled randomized studies is iloprost. The available data support its use in
patients with CLI unsuitable for any reopening procedure or in whom revascularization
attempts have failed. There is no available technique for identifying those who will respond, but
its relative safety suggests that it should be tried in all such patients unless an early amputation is
clearly unavoidable. Its usc as an adjuvant to high-risk revascularization procedures is being
assessed.
Recommendation 85: Use of prostanoids in critical limb ischemia
Patients who have a viable limb in whom revascularization procedures are impossible,
carry a poor chance of success or have previously failed, and particularly when the alter-
native is amputation, may be treated with prostanoids.
Critical Issue 29: Use of prostanoids in earlier stages of critical limb ischemia
There is a need to test prostanoids in patients with earlier stages of critical limb
ischemia and in whom intervention is predicted to have a relatively low success rate as
most randomized, open or double-blind trials with intraarterial or intravenous
prostanoids have been performed in patients with end-stage critical limb ischemia.
D 4.3.3 Pharmacotherapy Other Than Prostanoids
Antiplatelet drugs
Long-term treatment with aspirin and ticlopidine is shown to reduce the progression of femoral
atherosclerosis.if Whether these antiplatelet agents can prevent thrombosis in prosthetic
fernoropoplireal grafts is uncertain (see also D 4.13.2, Antiplatelet Therapy, p 5248). It should
be noted that in a recent study the favorable effect of ticlopidine over 24 months has been
demonstrated in patients after saphenous vein bypass grafting.t?
There is a strong case for treatment of all patients with PAD with long-term antiplatdet thera.py
such as aspirin, ticlopidine, or clopidogrel (see Recommendation 29, p S8S). Meta-a.nalysis of
the Final Report of the Second Cycle of the Antip\atdet Trialistsi Collaboration shows dear evi-
dence that these anriplatelet agents produce a 25% reduction of other vascular events (stroke,
myocardial infarction, and vascular death) and also improve patency of peripheral arteries ann
grafts.3D However, neither these trials nor the recent CArRIE study were conducted in PAD
patients with rest pain and ischemic ulcers.31
Anticoagulants
No clinical trials have been published on the use of unfractionated heparin for critical limb
ischemia, although recently an open study using low-molecular-weight heparin did show
encouraging results with a decrease ofrest pain and healing of ulcers previously resistant to
treatment.V None of the publications on the effect of anticoagulation exclusively concerns such
patients. The use of oral anticoagulants improved the long-term patency of infrainguinal bypass
grafts, but this single study should be confirmed.V (see also D 4.13, Adjuvant Therapy After
Revascularization, p 5247)
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Hemodilution
The benefit of hemodilution has not been properly evaluated in patients with chronic CLI;
however, if a patient's hematocrit remains 50% despite cessation of smoking and rehydration,
hemodilution may be considered.
Critical Issue 30: Use of lon~-term oral antithrombotic therapy in terms of limb survival
There is a need to determine whether long-term oral antithrombotic therapy is useful in
terms of limb survival.
Defibrinogenating agents
Despite many open trials reporting promising results with the use of defibrinogenating agents in
50%to 80% of treated patients 34,35,36 two recent placebo-controlled double-blind studies with
ancrod failed to show any benefit in terms of healing of ischemic ulcers or in reducing subse-
quent amputation rate. 37,38
Other vasoactive drugs
Although a few vasoactive drugs may have a beneficial effect in vasospastic diseases by increasing
cutaneous capillary flow, there is little substantive evidence to support their use on patients with
critical limb ischemia.39,40,41,42,43,44 Most vasoactive drugs are said to have vasodilatory proper-
ties, whereas some claim to alter blood rheology, improve tissue oxidative potential in the
ischemic state, or act by increasing collateral flow through a serotonergic blocking effect . Some
of these drugs have been shown to be efficacious in intermittent claudication (see B 4.2,
Pharmacotherapy for Symptoms of Intermittent Claudication, p 589), but none have been
shown to have a clinically beneficial effect in large properly controlled studies in patients with
severe chronic limb ischemia.
L-Arginine is the precursor of endogenous nitric oxide that is a potent vasodilator, acting via the
intracellular second-messenger cyclic guanosine monophosphate (cGMP) . In healthy humans, L-
arginine induces peripheral vasodilation and inhibits platelet aggregation because of increased
nitric oxide production.45,46 The clinical benefit of this in the treatment of CLI remains to be
established.
Parenteral pentoxifylline have been investigated in patients with critical limb ischemia in two
double-blind placebo -controlled multicenter trials. In the two trials, 600 mg pentoxifylline was
administered intravenously twice daily for up to 21 days. In the European Study Group, the
severity of rest pain was consistently and significantly lower in the pentoxifylline group, but
unfortunately the use of analgesics was allowed and uncontrolled (intention-to-treat analysis).47
Treatment response was not influenced by the presence of diabetes or by eligibility for surgery.
The subsequent double-blind Norwegian study followed the same protocol but in a smaller
number of patients. This study confirmed a trend in the amelioration of rest pain but did not
reach statistical significance between the two treatment groups .sf
Recommendation 86: Vasoactive drugs in treatment of critical limb ischemia
Very few vasoactive drugs have been properly investigated in patients with critical limb
ischemia. Because the results are unconvincing or negative, current drugs cannot be rec-
ommended in patients with chronic critical limb ischemia.
D 4.3.4 Gene-Induced Therapeutic Angiogenesis
Recent investigations have established the feasibility of using recombinant formulations of
angiogenic growth factors to expedite or augment collateral artery development in animal mod-
els of hind limb ischemia. Th.is novel strategy for the treatment of vascular insufficiency has been
termed "therapeutic angiogenesis. "49 No recombinant protein formulation of an angiogenic
cytokine has yet been made available tor human studies of CLI. Gene transfer constitutes an
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alternative strategy for accomplishing therapeutic angiogenesis. In the case of vascular endothe-
lial growth factor (VEGF), this is a particularly appealing strategy because the VEGF gene
encodes a signal sequence that permits the protein to be naturally secreted from intact cells50;
the impact of the gene product is thus not limited to the transfected cells, but can be amplified
considerably by paracrine effects of the gene product (VEGF protein) on endothelial cells
responsible for neovascularization.
Gene therapy for therapeutic angiogenesis was performed initially in patients with CLI byarteri-
al gene transfer ofVEGF plasmid DNA (phVEGF I65).51 Using a dose-escalating design, treat-
ment was initiated with 100 pg phVEGF 165. Three patients presenting with rest pain (but no
gangrene) and treated with 1,000 pg were subsequently shown at 1 year follow-up to have
improved blood flow to the ischemic limb and remain free of rest pain.52 With the increase in
dose of phVEGF165 to 2,000 pg, angiographic and histological evidence of new blood vessel
formation became apparent. 53
More recently, the use of intramuscular (1M) gene transfer, employed initially as a means of
treating patients in whom vascular disease in the ischemic limb was too extensive to permit an
intraarterial approach, resulted in marked improvement in collateral vessel development in
patients with CLI.54 The 1M strategy was performed in 10 limbs of nine patients with nonheal-
ing ischemic ulcers (n = 7/10) or rest pain (n '" 10/10) attributable to peripheral arterial dis-
ease. A dose of 4,000 pg phVEGF 165 was injected directly into the muscles of the ischemic
limb. Gene expression was documented by a transient increase in VEGF serum levels using an
enzyme-linked immunosorbent assay (ELISA). The ankle:brachial pressure index improved sig-
nificantly (from 0.33 ± 0.05 to 0.48 ( 0.03, P = 0.02); newly visible collateral blood vessels were
documented by contrast angiography in seven limbs; and MRA showed qualitative evidence of
improved distal flow in eight limbs. Ischemic ulcers healed or markedly improved in four of
seven limbs, including successful limb salvage in three patients recommended for below-knee
amputation. Complications were limited to transient lower extremity edema in six patients, con-
sistent with VEGF enhancement of vascular permeability. These findings may be cautiously
interpreted to indicate that intramuscular injection of naked plasmid DNA achieves constitutive
overexpression ofVEGF sufficient to induce therapeutic angiogenesis in selected patients with
CLI. Certain patients in this initial cohort and several others subsequently (seven limbs in six
patients) satisfied diagnostic criteria for Buerger's disease.55
Critical Issue 31: Use of gene-induced angiogenesis in patients with critical limb ischemia
There is a need, suggested by preliminary studies, for properly controlled studies of the
use of gene-induced angiogenesis in treatment of patients with critical limb ischemia.
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